CAR T-cell Therapy Development Services for Cancer
CAR T-cell therapy, an immunotherapy, which genetically engineers T-cells and then harnesses the power of the immune system to recognize and destroy cancer cells. Alfa Cytology is committed to the development of CAR T-cell therapies, advancing the modification of CAR T-cells to improve their potential efficacy and safety, offering a promising avenue for personalized cancer therapy.
Introduction to CAR T-cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy harness the power of the immune system, to target and eliminate cancer cells due to the ability of CARs to recognize and bind to specific proteins or antigens on the surface of cancer cells. Currently, available CAR T-cell therapies are made by collecting T-cells and re-engineering them in the lab to produce proteins called chimeric antigen receptors (CARs) on their surface. CAR T-cell therapies were initially developed to target acute lymphoblastic leukemia (ALL), which is the most common form of cancer in children. To date, CAR T-cells have become a common therapy for many types of hematologic malignancies such as lymphomas and leukemias. Research continues to explore ways to enhance the effectiveness and broaden the applicability of CAR T-cell therapy, including addressing challenges such as tumor heterogeneity, antigen escape, and cytokine release syndrome.
Fig.1 Mechanism of action of CAR T-cell therapy. (McGuirk, J., et al., 2017)
Our Services
Alfa Cytology's research and services cover the full range of strategies for CAR T-cell therapy development. We can collaborate with biotechnology companies, pharmaceutical companies, and any research organization wishing to develop CAR T-cell therapies, to advance basic science and translational research in CAR T-cell therapy. Our services include, but are not limited to, the following.
Target Identification and Validation
Identify tumor-specific antigens using bioinformatics tools and proprietary algorithms to select targets with high therapeutic potential and minimal off-target effects.
CAR T-cell Design
Optimize CAR construction using gene editing techniques and customize CAR design for specific tumor antigens to minimize the risk of immune evasion and antigen escape.
Preclinical Evaluation
Evaluate the efficacy, specificity, and safety of CAR T-cell therapies using advanced in vitro and in vivo models, to ensure the availability of candidate therapies.
Biomarker Discovery
Identify biomarkers and discover molecular signatures associated with therapeutic efficacy and drug resistance through multi-omics approaches and bioinformatics analysis.
Our Advantages
Alfa Cytology's technologies strength in CAR T-cell therapy development accelerate the translation of CAR T-cell therapies.
- Specialized Knowledge and Team. Deep expertise in immunology, oncology, and a multidisciplinary team of scientists to support you.
- Next-Generation Sequencing (NGS). Enables genomic profiling of tumors to identify targetable mutations and optimize CAR design.
- Microfluidics-based Cell Sorting. Facilitates precise isolation and purification of engineered T-cell populations.
- Artificial Intelligence (AI) Integration. Harnesses machine learning algorithms to analyze biological data and predict therapeutic responses.
Alfa Cytology offers a comprehensive suite of solutions to facilitate the development of highly effective and safe next-generation cancer therapies. Our extensive capabilities and tailored solutions enable stakeholders across the oncology field to drive innovation and deliver transformative therapies. Contact us today to learn more about how we can work together.
Reference
- McGuirk, J., et al.; (2017). Building blocks for institutional preparation of CTL019 delivery. Cytotherapy, 19(9), 1015-1024.
! For research use only.
Related Services
